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Objective: 1) Determine the pharmacokinetics of tramadol hydrochloride and its active 
metabolite, O-desmethyl-tramadol (M1) after administration through different routes in 
female and male C57Bl/6 mice. 2) Evaluate the stability of tramadol solutions.  
Methods: Mice received 25 mg kg-1 tramadol as bolus [intravenously (IV), intraperitoneally 
(IP), subcutaneously (SQ), orally per gavage (OSgavage)] or over 25 h [oral in drinking water 
(OSwater) or Syrspend®SF (OSSyrsp)]. Venous blood was sampled at predetermined time 
points to determine tramadol and M1 plasma concentrations (LC-MS/MS detection). 
Pharmacokinetic parameters were described using a non-compartmental model. The stability 
of tramadol in water (acidified and untreated) and Syrspend®SF (0.20 mg mL-1) at ambient 
conditions for 1 week was evaluated. 
Results: Tramadol showed low oral bioavailability (26%). After all administration routes 
Cmax of both tramadol and M1 were high (>100 ng mL-1 and >40 ng mL-1, respectively) 
and followed by short half-lives (2-6h). Plasma concentrations of tramadol and M1 after self-
administration remained stable throughout consumption time; except for M1 in Sysrpend®SF 
group. Short-lasting side effects were observed after IV. Water and Syrspend®SF solutions 
are stable for 1 week. 
Tramadol SQ (25 mg kg-1) followed by tramadol in water (25 mg kg-1 in 24 h) achieves 
plasma levels warranting efficacy assessment in further studies. 








Ziele: Bestimmung der Pharmakokinetik von Tramadol-Hydrochlorid und aktiven 
Metaboliten M1 nach Verabreichung über verschiedene Applikationsarten an männliche und 
weibliche C57BL/6-Mäuse. Bewertung der Stabilität von Tramadol-Lösungen Wasser 
und  Syrspend®SF  bei Raumtemperatur über eine Woche. 
 
Methoden: Den Mäusen wurde 25 mg kg
-1
 Tramadol  als Bolus (Intravenös , Intraperitoneal, 
Subkutan, oral per Gavage) oder über 25 Stunden hinweg Oral in Trinkwasser oder in 
Syrspend®SF verabreicht. Die Plasmakonzentrationen von Tramadol  und M1 wurden 
bestimmt (Flüssigchromatographie-Massenspektrometrie). Die Pharmakokinetik-Parameter 
wurden mithilfe eines nicht-kompartimentellen Modells beschrieben. 
 
Ergebnisse: Tramadol hat eine geringe Bioverfügbarkeit (26%). Bei den gewählten 
Applikationsarten war Cmax für T und M1 hoch (>100 ng mL-1, bzw. >40 ng mL-1) und 
zeigten kurze Halbwertszeiten (2-6 Stunden). Die Plasmaspiegel von T und M1 nach 
Selbstapplikation blieben während der gesamten Aufnahmezeit stabil, mit Ausnahme von M1 
in der Sysrpend®SF-Gruppe. Kurz-anhaltende Nebenwirkungen wurden nach IV-Applikation 
beobachtet. Wasser- und Syrspend®SF-Lösungen sind für eine Woche stabil. 
 
Durch subkutane Applikation von Tramadol gefolgt von Tramadol in Wasser (25 mg kg
-1
 in 
24 Stunden) können Plasmawerte erreicht werden, welche in einer Wirksamkeitsbewertung in 
späteren Studien überprüft werden sollten.  
 









Mice are widely used as laboratory models for surgical procedures. The provision of 
appropriate analgesia for peri- and postoperative pain is an ethical and legal imperative 
(Carbone 2011) and essential for scientific integrity as untreated pain is expected to affect the 
outcome data. However, providing an effective analgesic treatment for the target species is 
challenging for involved scientists (veterinarians, researchers, animal welfare bodies…) due 
to the biological peculiarities, the sparse published data of both the pharmacokinetics and 
efficacy of potentially relevant analgesics in the target species or strain, and finally the 
potential for interaction with the experimental read out.  
 
Mice as a prey species tend to hide signs of pain, which hampers the recognition and 
quantification of pain, contributing to the underuse of postoperative analgesics. To date, the 
spectrum of analgesics available for laboratory mice relies mainly on few opioids (i.e. 
buprenorphine) and NSAIDs (carprofen, meloxicam). While offering potentially good 
analgesic options for mice (Tubbs et al. 2011; Oyama et al. 2012; Jirkof et al. 2015), they 
have limitations. NSAIDs are accompanied by anti-inflammatory and immune-modulatory 
effects (Iñiguez et al. 1999; Paccani et al. 2002), hence, inappropriate for studies involving 
inflammation and the immune system. Additionally their efficacy is questionable based on 
latest evidence (Roughan et al. 2016). 
 
The μ-agonist opioids, apart from interfering with the immune response to some extent (Page 
2005; Franchi et al. 2007; Ricardo Buenaventura et al. 2008), present dose-dependent 
undesirable side effects, such as respiratory and gastrointestinal depression, 
tolerance/hyperalgesia or increased activity (Flecknell 1984; Hayes et al. 2000; Hau & 
Schapiro 2002; Ricardo Buenaventura et al. 2008; Grimm et al. 2015).  
Tramadol is a centrally acting synthetic opioid, structurally related to morphine and codeine 
(Kayser et al. 1992; Cannon et al. 2010; Zhang et al. 2014) used for the treatment of moderate 
to severe pain, both acute and chronic, in various species, including man (Lewis & Han 
1997). Its analgesic efficacy is dependent on a complex set of interactions between opioid, 
adrenergic and serotonin receptor mechanisms: as an opioid agonist, tramadol has some 
selectivity for the μ-receptor and binds weakly to κ- and δ-receptors; furthermore, it also 
activates the monoaminergic system, inhibiting the neuronal reuptake of serotonin (5-
hydroxytryptamine; 5-HT) and noradrenaline (NA; norepinephrine) (Driessen & Reimann 
1992; Sacerdote et al. 1997). Both opioid and monoaminergic systems are deeply involved in 
the modulation and inhibition of pain. The clinical efficacy of tramadol is highly related to its 
metabolism but among its over 20 well-known metabolites, only one has analgesic properties, 
the O-desmethyl-tramadol hydrochloride (M1), which has 200-fold higher affinity for μ-
receptors and up to 6-fold higher analgesic potency than tramadol itself (Raffa et al. 1993; 
Vullo et al. 2014).  As a result of its composite mechanism of action, tramadol at clinical 
doses does not induce respiratory depression or hemodynamic changes, common to other 
opioids with a higher μ receptor activity (Lewis & Han 1997; Grond et al. 1999; Rätsep et al. 
2013). In mice, central nervous system side effects have been reported such as restlessness or 
straub-tail (>10mg kg
-1
 IV) (Von G. Osterloch 1978; Matthiesen et al. 1998) and seizures at 
high doses (>80mg kg
-1
 IP) (Raffa & Stone 2008). 
Due to its relatively high benefit/risk ratio, favorable pharmacokinetic properties, low 
potential for drug interactions in humans and other animal species (Lewis & Han 1997), and 
non-controlled substance schedule, tramadol might be an interesting candidate to widen the 




controversial: a recent study demonstrated that tramadol ameliorates cyclophosphamide-
induced bladder-pain-related behaviors in mice (3-10 mg kg
-1 
orally given) (Oyama et al. 
2012) , while (Wolfe et al. 2015) do not recommend it as a sole analgesic after abdominal 
laparotomy in mice. However these studies had no PK profiles supporting the dynamic data. 
Usually in this species, analgesics are administered via subcutaneous (SQ) and intraperitoneal 
(IP) routes, a practice that may induce handling stress when carried out several times a day to 
ensure a seamless analgesia over time (Sharp et al. 2002). Pain treatment can be further 
improved by optimizing the methods of administration, (i.e. sustained/controlled release 
formulations or self-administration methods). Self-administration methods are an attractive 
option because they could ensure stable drug levels in the blood, which is necessary for 
adequate (in both intensity as duration) analgesic coverage while avoiding repetitive handling 
of the animals. Self-administration would resolve the stress caused by the repeated injection 
of drugs at defined intervals, depending on the species-specific pharmacokinetics. Therefore, 
in recent years self-administration methods using different types of vehicles (water, pellets, 
Nutella
®
, jelly) have been tested for oral drug delivery in laboratory animals with some 
success. There are already available data supporting this route of administration for 
analgesics (i.e. buprenorphine) in rats and mice (Abelson et al. 2012; Molina-Cimadevila et 
al. 2014); however, to the best of our knowledge, there is no published data regarding 
tramadol delivery in mice by such means. 
Based on the rationales expressed and knowledge gaps in the literature, this study aims to: 1) 
Determine the pharmacokinetics of tramadol and M1 after tramadol administration through 
different routes in female and male B6 mice. 2) Evaluate the stability of tramadol in aqueous 
solution, to explore the feasibility of using drinking water for tramadol delivery. 3) 
Determine the most suitable route or combination of routes for this strain. 
2.2 Materials and Methods 
Animals 
The experimental protocol was approved by the local veterinary authorities. Eighteen male 
and 18 female C57BL/6J mice (20-30 g body weight, BW) were used in this study. Inclusion 
criteria were: strain, age and BW, healthy on clinical examination and based on review of 
health reports (according to FELASA health monitoring recommendations) (Mähler et al. 
2014). Exclusion criteria were: failure to adhere to pre-test requirements or overt sign of 
illness. Mice were housed in groups of three animals in standard polycarbonate cages, with 
aspen wood bedding (J. Rettenmeier & Söhne GmbH, Germany) and nesting material; a 
rotational enrichment plan was in place, with hemp rope (Cordag AG, Switzerland) and aspen 
wood stick (LAB & VET Service GmbH, Austria) present in the home cages. Mice were 
acclimated in a reverse 12-h light and dark cycle (lights on at 6 PM and off at 6 AM) for a 
minimum of 7 days before the start of the study and kept in rooms with controlled 
temperature (20-22°C) and relative humidity (40-60%). Animals were housed in the same 
room in which the study was performed and had freely access to a rodent maintenance diet 
(Mouse and Rat Maintenance 3436 Kliba Nafag AG, Switzerland) and tap water. The facility 
is accredited by the Association for Assessment and Accreditation of Laboratory Care 
International (AAALACi). 
Study design 
Animals were randomly assigned with a prospective, blinded, parallel design to one of the 
administration groups [n= 3 females + 3 males/group; groups: intravenous (IV), 




drinking water (OSwater) and oral in Syrspend
®
SF PH4 Aroma-free (Fagron, Deutschland) 
(OSSyrsp) for 25 hours].  
All groups received 25 mg kg
-1
 of tramadol hydrochloride (Tramal
®
 100 injection solution, 
Grünenthal Group, Germany) either as a single dose or in drinking water or Syrspend
®
SF 
during 25 hours. 
Due to the small volume required, a dilution of Tramal
®
 100 in NaCl 0.9% (B. Braun 
Medical AG, Switzerland) with a final concentration of 6.25 mg mL
-1
 was used for IV, IP, 
SQ and OSgavage administration.  
For T in drinking water or Syrspend
®
SF groups a solution of 0.20 mg mL
-1
 was prepared. 
Assuming an average daily water intake of 3.75 mL and  25 g BW, a solution of 0.20 mg mL
-
1
 would ensure a dose of  25 mg kg
-1
 tramadol in 24 h (Harkness et al. 2013; Ingrao et al. 
2013).  
On the day of the experiment, the cage mates (n=3) were placed in metabolic cages and 
randomly assigned to one of the six treatments by drawing lots by the person administering 
the tramadol. A second operator, who was blinded to the administration routes, performed the 
blood collection at the determined time-points after drug administration; a volume of 50 μL 
of blood was drawn twice from each animal by tail-vein puncture with the conscious mice 
placed in a restrainer. The detail of the experimental set-up is depicted in Figure 1. 
Insert figure 1. 
All samples were collected into lithium-heparin-wetted tubes (POCT 50µl LH Minnivette, 
Sarstedt AG & Co, Germany) and stored in dry ice; plasma was separated by centrifugation at 
3000 g for 10 minutes and frozen at -20°C until analysis (Musshoff et al. 2006; Cooper & 
Negrusz 2013). 
Additionally, the stability of tramadol when diluted in different types of drinking water and 
Syrspend
®
SF was evaluated similar to the method described by Ingrao et al (2013). Tramadol 
(0.6 mL) was added to 150 mL water (bottle 1: non acidified water, F. Hoffmann-La Roche, 
Basel; bottle 2: non acidified water Unispital, Zürich; bottle 3: acidified water, F. Hoffmann-
La Roche, Basel; bottle 4: acidified water, Unispital, Zürich) or Syrspend
®
SF (bottle 5), to 
achieve a final concentration of T (0.20 mg mL
-1
). Water was non-chlorinated drinking-
quality from the local water companies IWB (Basel-Stadt) and EWZ (Zurich). Full physico-
chemical analysis was performed monthly and bacteriological quarterly (see Appendix 1). 
The acidified water was first filtered and demineralized and then acidified by adding HCl 
(ProMinent Dosiertechnik AG, Switzerland) until reaching a pH of 2.6-3.0. 
All bottles were stored at ambient light and temperature conditions for up to 1 week. Samples 
were taken at 0, 24, 48 and 72 h and 7 days after the preparation of the solution and stored at 
-20°C until analysis (Musshoff et al. 2006; Cooper & Negrusz 2013). 
Liquid chromatography and tandem mass spectrometry (LC-MS/MS) 
Tramadol and M1 plasma concentrations were determined using liquid chromatography (LC) 
(Shimadzu Prominence, USA) coupled with mass spectrometry API 5500 (MS/MS) 
(ABSciex, USA ). Plasma samples were processed using a protein precipitation procedure. A 
volume of 30 µl of methanol were added to 0.5 µl of plasma in 384 wells plate, agitated and 





Mobile phase consisted of A: 10 mM Amonium acetate in water + 0.05% acetic acid (v:v), B: 
Methanol + 0.05% acetic acid (v:v). Flow rate was 0.8 mL min
-1
. The run gradient started at 
95%A / 5%B for 0.3 min then over 0.6 min, with a linear gradient to 20%A / 80%B, then 
over 1.2 min with a linear gradient to 5% / 95% B, returning to 95%A/ 5%B over 1.8 min 
with a linear gradient. Total run time was 3.9 min. Separation was achieved using a 2.1 x 30.0 
mm column (C18 Ascentis express; Supelco, Sigma-Aldrich Corporation, Switzerland) 
maintained at 50°C. 
Transition for tramadol was: parent ion (m/z) 263.9, daughter ion (m/z) 58.1; for M1: parent 
ion (m/z) 249.9, daughter ion (m/z) 58.1. 
The analytical range for tramadol was 5-10000 ng mL
-1
 and for M1 was 25-10000 ng mL
-1
. 
Standards extracted from spiked blank plasma gave calibration curves over the dynamic 
range. QC samples were run in replicates of 2 at a concentration of 5, 50 and 500 ng mL
-1
 for 
tramadol. Accuracy was assessed at each standard and QC level, all data points were within 
±15% or ±20% at the lower limit of quantification (LLOQ) and upper limit of quantification 
(ULOQ). 
Pharmacokinetic and data analysis 
Non-compartmental pharmacokinetic analyses (NCA) were performed with computer 
software (Phoenix WinNonlin Version 6.4; Pharsight Corp., CA, USA). The following 
pharmacokinetic parameters were calculated from the composite plasma concentration data 
after IV administration: the area under the curve (AUClast) from time 0 to the last time point 
above the analytical LLOQ, the AUC extrapolated to infinity (AUCinf), the percentage of the 
AUClast extrapolated to infinity (AUCextrap), plasma clearance (Cl), terminal half-life (t½), 
terminal rate constant (λz), volume of distribution at steady state (Vd), and apparent volume 
of distribution of the area during the elimination phase (Vz). The concentration at time 0 (C0) 
was calculated by log linear back extrapolation using the first two time points after IV 
administration. The λz was determined using at least three time points. Pharmacokinetic 
parameters after extravascular administration (IP, SC, OSgavage) from the composite plasma 
concentration data included the AUClast, AUCinf, t½, λz, plasma clearance per fraction of the 
dose absorbed (Cl/F), and apparent volume of distribution of the area during the elimination 
phase per fraction of the dose absorbed (Vz/F). The fraction of the dose absorbed (F) after 
extravascular administration was determined by dividing the oral AUCinf by the IV AUCinf. 
The maximum plasma concentration (Cmax) and time to maximum plasma concentration 
(Tmax) were determined directly from the plasma concentration data. The ratios of 




The measured concentration of the injectable tramadol (Tramal
®
 100) dilution in water (both 
acidified and non-acidified) and Syrspend
®
SF ranged from 0.193 mg mL
-1
 to 0.230 mg mL
-1
 
(time 0 in Syrspend
®
SF was considered an artefact and therefore excluded), and remained 
stable for 7 days under ambient conditions (Fig. 2). 




The  measured concentration of the injectable tramadol dilution in NaCl 0.9% (targeted to 
achieve a final concentration of 6.25 mg mL
-1
) used for the parenteral and OSgavage 
administration ranged between 6.24-6.34 mg mL
-1
 confirming the accuracy of the 
extemporaneous solution and was stable for 24 h under ambient conditions. 
In vivo 
After IV administration mild to moderate incoordination, ataxia, and straub tail were 
observed in all animals, the duration of these side effects being no longer than 40 seconds. In 
all other treatment groups no clinically evident side effect was observed. 
Individual and mean plasma concentrations of tramadol and M1 were plotted versus time for 
each administration route (Fig. 3-6). The pharmacokinetic parameters for tramadol and M1 
calculated from the composite concentration data for both genders combined are presented in 
Tables 1, 2 and 3. 
Following IV administration, tramadol and M1 were quantifiable through 4 h and 2 h post-
dose, respectively. Tramadol had high systemic clearance of approximately 160 mL/min/kg, 
large volume of distribution (Vd > 7.2L kg
-1
), and short plasma half-life (<1 h). Exposure to 
M1, in terms of Cmax and AUClast, was 15% and 20%, respectively, of the exposure to the 
parent drug. 
Following IP administration, tramadol and M1 were quantifiable through 4 h and 2 h post-
dose, respectively. Bioavailability for tramadol was 67%.   
Following SQ administration, tramadol and M1 were quantifiable through 7 h post-dose. 
Systemic exposure in terms of AUC was comparable between the two routes. Furthermore, 
systemic exposure to M1 following SQ administration was ≥2-fold higher than M1 exposure 
after IV dosing, likely as a result from the prolonged absorption of the parent drug. 
Following OSgavage administration, tramadol and M1 were quantifiable through 7 h post-dose. 
Peak plasma concentration was reached at 1 h post-dosing. Oral bioavailability was 26% 
reflecting the extent of absorption and pre-systemic clearance due mostly to metabolism. 
Indeed, peak plasma concentration of M1 was comparable to that of the parent drug, while 
the metabolite to parent ratio was 1.3/1.5 for AUClast/AUCinf, respectively. 
Insert tables 1 and 2 
Apparent terminal half-life for the extravascular routes (1.4 h IP and 1.7 h OSgavage and SQ) 
was twice the value of the estimated half-life after IV dosing and is suggestive of a flip-flop 
kinetics, e.g. absorption, rather than elimination, was the rate limiting step in tramadol 
systemic disposition and elimination, thus the estimated half-lives represent the absorption 
half-lives. The concentration profiles after IP and SC administration (Figure 3b and c) are 
suggestive of biphasic absorption and/or enterohepatic recycling, but no definitive conclusion 
could be made due to the limited number of animals and sampling time points.  
The minimal tramadol plasma concentration for analgesic effect in humans has been 
estimated to be 100 ng mL
-1
 (Lewis & Han 1997), however, the threshold concentration in 
mice is not known. We used the 100 ng mL
-1 
concentration as a target level to achieve and 




concentrations above and around 100 ng mL
-1
 were maintained over 2 to 4 h post-dosing, 
while, after SQ administration, values remained above 100 ng mL 
-1
 for almost 6 hours. 
Insert figures 3a-d and 4a-d. 
After OSSyrsp and OSwater administration, Cmax values were similar (328 and 315 ng mL
-1
, 
respectively). With oral self-administration of tramadol diluted in Syrspend
®
SF, almost 6 
hours were necessary to reach mean tramadol plasma levels above 100 ng mL
-1
. Following 
this, mean tramadol concentrations remained stable (>200 ng mL
-1
) until replacement of the 
drinking bottle with plain solutions. Conversely, mean tramadol concentrations above 150 ng 
mL
-1
 were reached after only 3 h when tramadol was diluted in water and remained above 
100 ng mL
-1
 during consumption time (Fig. 5a-b). 
High M1 concentrations (>100 ng mL
-1
) where found in the OSwater group during 
consumption time, but 1 h after stopping the treatment, plasma concentration was half the 
concentration at 25 h. In the OSSyrsp M1 could be detected only at one time-point, at 7 h (67.5 
ng mL
-1
) (Fig. 6). 
Insert figures 5a-b and 6a-b. 
Insert table 3. 
Unfortunately, due to an unexpected leak in several bottles used, it was not possible to 
quantify water/Syrspend
®
SF intake as planned. 
2.4 Discussion 
The disposition and pharmacokinetics of a potentially clinically relevant dose of tramadol and 
its metabolite M1 after different routes of administration have been characterized for the first 
time in female and male B6 mice. 
The plasma levels of both tramadol and M1 in B6 mice were high and in the analgesic range 
described for humans (Lehmann et al. 1990; Lewis & Han 1997) for up to 2 hours after IV 
with the greatest duration (6 hours) being after SQ administration. Therefore the expected 
analgesic effect of a single dose tramadol in this strain is likely to be of short duration 
depending on the administration route. Oral bioavailability after a single gavage dose was 
lower than that reported in other species (Lintz et al. 1986; Pypendop & Ilkiw 2008). 
However, when tramadol was administered in water or Syrspend
®
SF, the plasma levels 
achieved were high and remained stable during consumption time (25 h), which implies that 
animals kept voluntarily drinking the solution during that time, including their inactive phase 
during the day. 
In compliance with the 3R principles (Russell et al. 1959; Carbone 2011), a sparse sampling 
design was used in this study with the minimal number of animals (N = 2 time 
points/gender). Following the recommendations of National Centre for the Replacement, 
Refinement and Reduction of Animals in Research (https://www.nc3rs.org.uk/mouse-
decision-tree-blood-sampling), a maximum volume of blood of 0.01mL/mouse (<1% total 
blood volume) was collected in 24 hours.  The data did not allowed to perform 
pharmacokinetic analysis beyond NCA, however, the results of the analysis are sufficient for 
assessing the exposure of the mice after different administration routes and prospective dose 




The dose tested in the present study was selected based on information obtained from a wide 
literature review and the extrapolation of doses from other species. For use in mice the Board 
for Anesthesia and Analgesia of the GV-SOLAS recommends the oral self-administration 
route with tramadol diluted in water at a concentration of 1mg mL
-1 
(Julia Henke 2015) 
resulting in a dose of 125 mg kg
-1
 of T in 24 h. However, no pharmacokinetic/ 
pharmacodynamic (PKPD) data are available to confirm that such a high dose is necessary 
and the higher the dose, the more likely to induce side-effects and bias research outcomes, 
which is highly undesirable and the #1 argument to avoid analgesic use in experimental mice 
(Gaspani et al. 2002).  
Overall, the pharmacokinetic parameters of tramadol reported in the current study are in 
accordance with those obtained by Matthiesen et al. (1998) after 30 mg kg
-1
 tramadol orally 
given in mice: with high plasma concentrations (Cmax above 300 ng mL
-1
), short half-life 
(<2 h) and similar AUC values. No comparisons can be made for the other administration 
routes. 
Tramadol-induced analgesia results from both a monoaminergic and an opioidergic effect; 
the monoaminergic effect is activated mostly by tramadol, while M1 is the main responsible 
for the opioidergic effect, being up to 6 times more potent as analgesic as tramadol itself. 
Therefore, the metabolism of tramadol is key to its analgesic action. Tramadol is metabolized 
in the liver by the cytochrome p450 enzyme system and is responsible for the variability 
among species in the pharmacokinetics and metabolism (Raffa et al. 1993; Wu et al. 2001; 
Martignoni et al. 2006) and consequent analgesic efficacy of tramadol (Desmeules et al. 
1996; Rukhshanda Saleem 2014). In the current study M1 concentrations paralleled tramadol 
concentrations after all administration routes, suggesting a rapid metabolism of tramadol to 
M1 in B6 mice. The faster metabolism in rodents compared to other species (Matthiesen et al. 
1998; White & Seymour 2005) could explain the low bioavailability (F) found in mice in the 
current study (26%) after a single oral dose compared to humans (70%) (Lintz et al. 1986), 
horses 64% (immediate release capsules) (Giorgi et al. 2007) or cats (93%) (Pypendop & 
Ilkiw 2008). Nonetheless, a species-specific lower absorption of tramadol in the small 
intestine, contributing to a lower bioavailability cannot be excluded. Furthermore, results 
show a rather short half-life for both tramadol and M1 for mice in any of the routes tested 
compared to humans (Lewis & Han 1997). Due to the short elimination half-life observed, a 
frequent dosing will be required to maintain targeted plasma concentrations. 
In humans, the minimal effective analgesic plasma concentration (MEC) of tramadol reported 
is 100 ng mL
-1
, and for M1 a range of 39.6±29.5 ng mL
-1
 has been established (Lehmann et 
al. 1990; Lewis & Han 1997). In the present study, mean tramadol Cmax were above 300 ng 
mL
-1
 with all routes of administration and plasma concentrations of both tramadol and M1 
were above the aforementioned minimal effective analgesic concentration range for humans. 
Hence, if the MECs reported in humans apply to mice also, it might be expected to achieve 
some level of analgesic effect with the dosage selected (25 mg kg
-1
), the duration of which 
would vary according to the route, but this need to be assessed in an appropriate PKPD 
experimental setting. 
In this study, although the highest plasma concentrations of both tramadol and M1 in mice 
were observed in the IV and IP groups, their concentrations decreased very fast and M1 
concentrations were below the LLOQ after 2 h of the treatment, hence no analgesic effect 




The most clinically relevant pharmacokinetic profile resulted after SQ administration: the 
targeted “potentially analgesic” plasma concentrations (T=100 ng mL-1 and M1=40 ng mL-1) 
were extensively exceeded within 0.5 h and then maintained for as long as 6 hours. Therefore 
tramadol administered SQ could provide an early onset of and continuous antinociception for 
up to 6 h in B6 mice. 
The half-life of tramadol and M1 in mice after a single dose is short, independently of the 
administration route, meaning that repetitive injections become necessary to achieve constant 
effective plasma levels over time. In laboratory rodents handling is associated with stress 
(Sharp et al. 2002; Jirkof et al. 2015) and should be avoided, not only for animal welfare but 
also as stress can bias the outcome data. Thus, self-administration methods or sustained 
release formulations are very attractive because they should ensure stable blood drug levels, 
while avoiding repetitive handling of the animals. 
In addition to drinking water, non-flavored syrup (Syrspend
®
SF) was also selected as vehicle 
to potentially improve self-administration of the dissolved tramadol. Before use, the stability 
of tramadol in both vehicles for up to a week at ambient conditions was confirmed, 
warranting its practical use. Ingrao et al (2013) performed a stability analysis of meloxicam 
and carprofen in water in ambient dark, ambient light and 4°C dark conditions. However we 
intended to reproduce the same conditions that we find in our animal facility, thus testing our 
solutions in ambient light conditions was optimal for our purpose. 
Mice were kept in a reverse 12 h light and dark cycle to match their peak circadian activity 
and hence fluid intake, providing more consistent data for the self-administration methods 
(OSwater and OSSyrsp ), Ingrao et al (2013). 
Time to reach Cmax with auto-consumption was 3h and 7h for the mice drinking medicated 
water or the syrup suspension, respectively). Mice are a neophobic species (Kronenberger & 
Médioni 1985; Molina-Cimadevila et al. 2014) and the lack of habituation to Syrspend
®
SF 
before the beginning of the study might have contributed to this outcome, nevertheless a 
lower intestinal absorption rate of tramadol in Syrspend
®
SF could be of importance as well. 
Plasma levels were high and constant over consumption time in both self-administration 
groups proving that tramadol in water and Syrspend
®
SF and at the dose chosen (25 mg kg
-1
 
in 24 h), is palatable and well accepted by the animals. Unfortunately due to constant leaks 
from the bottle it was not possible to measure water/Syrspend
®
SF consumption in this 
setting. 
An interesting finding was the detection of M1 only at the 7 h time-point in the OSSyrsp group. 
After ruling out any analytical issues and a possible interference of any of the components of 
Syrspend
®
SF in the metabolism of tramadol, this observation remains currently unexplained. 
It is possible that Syrspend
®
SF – a food starch based vehicle- might slow the rate of intestinal 
absorption of tramadol. Thus, as tramadol is absorbed, it is transformed to M1 and eliminated 
without reaching measurable concentrations in plasma. This could account also for the delay 
in Tmax observed in this group, as no tramadol accumulation in blood occurs until hepatic 
saturation. 
In the present study some mild and very transient side effects (incoordination and straub-tail) 
(Zarrindast et al. 2001), were observed after IV administration only and are in accordance 
with those found in the literature with seizures and sedation in mice and rats (Von G. 
Osterloch 1978; Raffa & Stone 2008; Cannon et al. 2010) and  dizziness, headache, nausea 




avoid side effects following this route in humans and other species (Lewis & Han 1997; 
McMillan et al. 2008; Shilo et al. 2008); however in mice, this would be difficult to 
implement due to the small volume needed and the stress implied. In rats skin lesions 
following SQ administration (25 mg kg
-1
) have been reported (Cannon et al. 2010), however 
this was not observed in any of the B6 mice.  
In this study, females appear to have consistently lower concentrations of tramadol than 
males, except for the OSwater group, but a relevance of possible gender differences needs to be 
established in future studies with larger sample size. In addition, B6 mice were chosen 
because this is the most widely used strain in research, however further studies for the 
evaluation of possible strain differences would be of interest. 
This study provides basic pharmacokinetic parameters for tramadol in B6 mice. 1) At the 
dose given, high plasma concentrations of both tramadol and its active metabolite M1 were 
obtained followed by a short half-life of 2 to 6 hours depending on the administration route. 
2) Tramadol is stable in aqueous solutions for up to a week at ambient conditions and 3) self-
administration of medicated water containing tramadol at a concentration of 0.20 mg mL
-1
 
was successful in achieving constant plasma levels over consumption time. 
Prospectively, this will allow selecting clinically relevant dose regimens for further 
pharmacodynamic testing in order to quantify objectively antinociceptive activity of tramadol 








Table 1. Pharmacokinetic parameters for tramadol in B6 mice. Single 25 mg kg
-1
 T dose, 
administered IV, SQ, IP and oral (gavage). SE = Standard error; NA = Not applicable;  
NR = Not reportable (r
2
<0.8). Results are presented with 3 significant figures. 
Tramadol Dosing Route 
PK Parameter (±SE)  Units IV  Oral IP SQ 
C0 (ng/mL) 3450 NA NA NA 
Cmax (ng/mL) 3710 (±1010) 347 (±170) 3010 (±410) 1870 (±575) 
Tmax (h) 0.25 1 0.08 0.25 
Tlast (h) 4 7 4 7 
AUClast (h*ng/mL) 2580 (±265) 652 (±43.4) 1520 (±213) 2760 (±1060) 
AUCinf (h*ng/mL) 2610 677 1750 2940 
AUCextrap (%) 1.39 3.59 13.3 6.40 
Cl or Cl/F (mL/h/kg) 159 616 238 141 
Vd (mL/kg) 7,200 NA NA NA 
Vz or Vz/F (mL/kg) 10,100 89,400 27,700 20,400 
t½ (h) 0.734 1.68 NR 1.67 






Table 2. Pharmacokinetic parameters for the active metabolite, O-desmethyltramadol (M1) in 
B6 mice (from composite data for genders combined). Single 25 mg kg
-1
 T dose, 
administered IV, SQ, IP and oral (gavage). SE = Standard error; NC = Not calculable. Results 
are presented with 3 significant figures. 
M1  Dosing Route 
PK Parameter (± SE)  Units IV  Oral IP SQ 
Cmax (ng/mL) 549 (± 272) 313 (± 11.8) 487 (± 4.62) 735 (± 19.6) 
Tmax (h) 1 0.5 0.25 0.5 
Tlast (h) 2 7 2 7 
AUClast (h*ng/mL) 509 (± 233) 850 (± 208) 434 (± 33) 1630 (± 86.2) 
AUCinf (h*ng/mL) NC 1010 NC 2040 
AUCextrap (%) NC 15.9 NC 19.9 
t½ (h) NC 2.37 1.17 2.76 
M1/T Ratio (Cmax)   0.148 0.902 0.162 0.393 






Table 3. Pharmacokinetic parameters for T and M1 in mice after self-administration in 
drinking water (from composite data for genders combined). Target dose of 25 mg kg
-1
 /24h 
based on water consumption of 3mL/animal/24h. M1 was quantifiable at a single time point 
for both genders and, therefore, no PK parameters were calculated reported.  SE = Standard 
error. 
Analyte Formulation 
Cmax (± SE) AUC(0-25h) AUClast (± SE) 
(ng/mL) (h*ng/mL) (h*ng/mL) 
Tramadol 
T in Syrspend 315 (± 69.5) 5450 6170 (± 2240) 
T in water 328 (± 146) 4330 4630 (± 1940) 











Figure 1. Sampling set-up: 3 mice/ gender were allocated to each administration group and 
two 50 μL samples/mouse were collected. These data points were used to create a composite 








Mouse # Sampling times post IP/IV dosing 
♀ ♂ 5 min 15 min 30 min 1 h 2 h 4 h 
1 4 x x 
2 5 x x 
3 6 x x 
 
c) 
Mouse # Sampling times from start of drinking water /Syrspend
®
 self-dosing 
♀ ♂ 1 h 3 h 7 h 25 h* 26 h 31 h 
1 4 x x 
2 5 x x 
3 6 x x 
* replaced with plain solution 
 
  
Mouse # Sampling times post SQ/Oral (gavage) dosing 
♀ ♂ 15 min 30 min 1 h 2 h 4 h 7 h 
1 4 x x 
2 5 x x 




Figure 2. Stability of tramadol HCl injectable solution (T; Tramal
®





SF, Basel acidified, Basel non-treated, Zurich acidified and Zurich non-treated 
water and held at ambient conditions for 7 days. 
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Figure 3. Semi-log composite plots of female, male and mean plasma T concentrations over 
time after a) IV, b) IP, c) SQ and d) OSgavage administration of 25 mg kg
-1 
T. The horizontal 
line represents the minimal effective analgesic plasma level of T (100 ng mL
-1
) in humans. 
Females, males,  mean. 
0 2 4 6 8
1 0
1 0 0
1 0 0 0
1 0 0 0 0
T ra m a d o l IV  B o lu s




















F e m a le
M a les
(a )
0 2 4 6 8
1 0
1 0 0
1 0 0 0
1 0 0 0 0
T r a m a d o l IP




















F e m a le
M ale
(b )
0 2 4 6 8
1 0
1 0 0
1 0 0 0
1 0 0 0 0
T ra m a d o l S Q




















F e m a le
M ale
(c )
0 2 4 6 8
1 0
1 0 0
1 0 0 0
1 0 0 0 0
T ra m a d o l O ra l (g a v a g e )






























Figure 4. Semi-log composite plots of female, male and mean plasma M1 concentrations 
over time after a) IV bolus, b) IP, c) SQ and d) OSgavage administration of T. The horizontal 
line represents the minimal effective analgesic plasma level of M1 (40 ng mL
-1
) in humans. 
After 25 h (arrow) the drinking water/Syrspend
®
SF were replaced with plain solutions. 
Females, males,  mean. 
0 2 4 6 8
1 0
1 0 0
1 0 0 0
1 0 0 0 0
M 1  IV  B o lu s




















F e m a le
M ale
0 2 4 6 8
1 0
1 0 0
1 0 0 0
1 0 0 0 0
M 1  IP




















F e m a le
M ale
0 2 4 6 8
1 0
1 0 0
1 0 0 0
1 0 0 0 0
M 1  S Q




















F e m a le
M ale
0 2 4 6 8
1 0
1 0 0
1 0 0 0
1 0 0 0 0
M 1  O r a l




























Figure 5. Semi-log composite plots of female, male and mean plasma T concentrations over 
time in a) OSwater and b) OSSyrsp  administration of 25 mg kg
-1 
T over 25 h. After 25 h (arrow) 
the drinking water/ Syrspend
®
SF were replaced with plain solutions. The horizontal line 
represents the minimal effective analgesic plasma level of T (100 ng mL
-1
) in humans. 
Females, males,  mean. 
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Figure 6. Semi-log composite plots of female, male and mean plasma M1 concentrations 
over time in a) OSwater and b)OSSyrsp groups. After 25 h (arrow) the drinking water/Syrspend® 
SF were replaced with plain solutions. The horizontal line represents the minimal effective 
analgesic plasma level of M1 (40 ng mL
-1
) in humans. Females, males,  mean. 
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